It comes that the combining EGFR-TKIs with angiogenesis inhibitors therapy, compares to EGFR-TKIs monotherapy, prolonged the PFS of advanced NSCLC patients carrying 19Del mutation [HR:0.62 (95%CI: 0.53~0.73, P<0.00001)] (Fig. 3). This evidence concerns the gene EGFR and non-small cell lung carcinoma.